Clinical and Experimental Metallodrugs in Medicine: Cancer Chemotherapy

The main goal of this symposium is to advance anticancer metallodrug research and to use research findings for the development of new therapies by promoting collaborations among medicinal inorganic chemists and investigators in complementary fields. This event is intended as an open forum that will include anticancer metallodrug experts along with pharmacologists, translational medicine researchers, scientists from pharmaceutical companies working in oncology drug development, clinicians and scientists/program officers from the US National Institutes of Health/National Cancer Institute.
read more


ORGANIZERS

Chair: Maria Contel, is an Associate Professor of Inorganic Chemistry at Brooklyn College, the City University of New York (CUNY). She also serves as a faculty member for the Chemistry and Biology Doctoral Programs at the Graduate Center (CUNY) and is an Associate Member of the University of Hawaii, Cancer Center (Natural Products and Experimental Therapeutics Program). Her research interests are in the area of inorganic chemistry, including organometallic, bioinorganic and medicinal chemistry, homogenous catalysis and green chemistry.

Co-Chair: Angela Casini is Chair of Medicinal and Bioinorganic Chemistry at the School of Chemistry of the University of Cardiff since 2015. Her research focuses on the study of anticancer metallodrugs' mechanisms of action and toxicity, as well as on the development of metal compounds as chemical probes to detect protein functions. In 2012 she received the EUROBIC11 Medal for Biological Inorganic Chemistry for her contribution to the research on metal ions in biological systems.

 Secretary: Guangyu Zhu is an Assistant Professor in the Department of Biology and Chemistry at the City University of Hong Kong. His research focuses on the synthesis and biological evaluation of novel metal-based anticancer agents, the development of cancer-specific nanomedicine to reduce cisplatin resistance, and the screening of biologically active small-molecule anticancer agents and their target validation.

International Adviser: Gianni Sava, Professor of Pharmacology at the University of Trieste is the Scientific Director at the Callerio Foundation Onus, a private non-profit research institute. Prof. Sava has a long lasting expertise in the study of chemicals against tumor metastases and he is the father of the pharmacological development of the ruthenium-based antitumour drug NAMI-A.

Local Organizing Committee Director: Joe W. Ramos, Professor of Cancer Biology is the Director of the Cancer Biology Program at the University of Hawaii Cancer Center. His research focuses on understanding the underlying mechanisms that control cancer cell proliferation and metastasis. In particular, his interests include how regulation of the ERK MAP kinase pathway contributes to pathogenic behaviors.